Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in previously untreated mantle cell lymphoma
MOH_2017-04-19_000212Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Acalabrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Started Feb 2017; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on MOH_2017-04-19_000212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-19_000212.